tirzepatide crohn's disease Patients with stable inflammatory bowel (IBD) and comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse tirzepatide crohn's disease tirzepatide and

All of these treatments can be used for adults, but each has a different age limit for children

In November 2025, the Trump administration announced landmark agreements with Eli Lilly and Novo Nordisk reducing the monthly price of GLP-1 weight-loss drugs from over $1,000 to as low as $245 for eligible patients

Patients who receive and consistently take the medication report results consistent with clinical trial data: 10 to 15% body weight loss over 6 to 12 months on semaglutide, and up to 20%+ on tirzepatide

Additionally, older adults are more likely to have pre-existing nutritional deficiencies, thyroid dysfunction, and polypharmacy that contributes to hair loss